| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
Spirochete infected tissue |
| Verdünnung |
- |
| Isotyp |
not determined |
| Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
RUO |
AVR135G |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
IF |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Staphylococcus aureus ATCC27660 |
Staphylococcus aureus
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
619-0198 |
-
|
| Host |
Rabbit |
| Klon |
ZR289 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Solitary fibrous tumor. |
| Verdünnung |
1:100-200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human STAT6 protein |
| Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
1.0 ml |
Concentrate |
CE/IVD |
Z2727RL |
-
|
| Host |
Rabbit |
| Klon |
ZR289 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Solitary fibrous tumor. |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human STAT6 protein |
| Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
7ml |
ready-to-use |
CE/IVD |
Z2727RP |
-
|
| Host |
Rabbit |
| Klon |
ZR289 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Solitary fibrous tumor. |
| Verdünnung |
1:100-200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human STAT6 protein |
| Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
0.5 ml |
Concentrate |
CE/IVD |
Z2727RS |
-
|
| Host |
Rabbit |
| Klon |
ZR289 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Solitary fibrous tumor. |
| Verdünnung |
1:100-200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human STAT6 protein |
| Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
0.1 ml |
Concentrate |
CE/IVD |
Z2727RT |
-
|
| Host |
Mouse |
| Klon |
N1665 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Adrenal cortical carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
| Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
1.0 ml |
Concentrate |
CE/IVD |
Z2223ML |
-
|
| Host |
Mouse |
| Klon |
N1665 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Adrenal cortical carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
| Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
7 ml |
Ready-to-use |
CE/IVD |
Z2223MP |
-
|
| Host |
Mouse |
| Klon |
N1665 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Adrenal cortical carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
| Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
0.5 ml |
Concentrate |
CE/IVD |
Z2223MS |
-
|
| Host |
Mouse |
| Klon |
N1665 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Adrenal cortical carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
| Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
0.1 ml |
Concentrate |
CE/IVD |
Z2223MT |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM124 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lung adenocarcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
| Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
1 ml |
Concentrate |
CE/IVD |
Z2428ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM124 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lung adenocarcinoma |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
| Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
7 ml |
Ready-to-use |
CE/IVD |
Z2428MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM124 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lung adenocarcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
| Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
0.5 ml |
Concentrate |
CE/IVD |
Z2428MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM124 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lung adenocarcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
| Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
0.1 ml |
Concentrate |
CE/IVD |
Z2428MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
MS, RT, BV, PG |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas, Pheochromocytoma |
| Verdünnung |
1:300 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide of human synaptophysin. |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
519-2172 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
MS, RT, BV, PG |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas, Pheochromocytoma |
| Verdünnung |
1:300 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide of human synaptophysin. |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
519-2174 |
-
|
| Host |
Rabbit |
| Klon |
SP11 |
| Format |
Concentrate |
| Reaktivität |
MS, RT, BV |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas or Pheochromocytoma |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human Synaptophysin |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
SP11 |
0.5 ml |
Concentrate |
RUO |
519-3112 |
-
|
| Host |
Rabbit |
| Klon |
SP11 |
| Format |
Concentrate |
| Reaktivität |
MS, RT, BV |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas or Pheochromocytoma |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human Synaptophysin |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
SP11 |
1 ml |
Concentrate |
RUO |
519-3114 |
-
|
| Host |
Mouse |
| Klon |
27G12 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Pancreas, colon |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Biocare Medical |
27G12 |
6 ml |
Ready-to-use |
CE/IVD |
AVI371G |
-
|
| Host |
Mouse |
| Klon |
SYP02 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Diagnostic Biosystems |
SYP02 |
1 ml |
Concentrate |
CE/IVD |
MOB399 |
-
|
| Host |
Mouse |
| Klon |
SYP02 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Diagnostic Biosystems |
SYP02 |
0.1 ml |
Concentrate |
CE/IVD |
MOB399-01 |
-
|
| Host |
Mouse |
| Klon |
SYP02 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Diagnostic Biosystems |
SYP02 |
0.5 ml |
Concentrate |
CE/IVD |
MOB399-05 |
-
|
| Host |
Mouse |
| Klon |
SYP02 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
ready-to-use |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Diagnostic Biosystems |
SYP02 |
6 ml |
Concentrate |
CE/IVD |
PDM592 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM208 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthetic peptide within Human Synaptophysin aa 200-300 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Zeta Corporation |
ZM208 |
1 ml |
Concentrate |
CE/IVD |
Z2544ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM208 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthetic peptide within Human Synaptophysin aa 200-300 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Zeta Corporation |
ZM208 |
7 ml |
Ready-to-use |
CE/IVD |
Z2544MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM208 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthetic peptide within Human Synaptophysin aa 200-300 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Zeta Corporation |
ZM208 |
0.5 ml |
Concentrate |
CE/IVD |
Z2544MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM208 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthetic peptide within Human Synaptophysin aa 200-300 |
| Lokalisation |
Cytoplasm |
Synaptophysin
|
Zeta Corporation |
ZM208 |
0.1 ml |
Concentrate |
CE/IVD |
Z2544MT |
-
|
| Host |
Rabbit |
| Klon |
SP70 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from N-terminus of human tau protein. |
| Lokalisation |
Cytoplasm |
TAU
|
Zytomed Systems GmbH |
SP70 |
1 ml |
Concentrate |
RUO |
520-3704 |
-
|
| Host |
Mouse |
| Klon |
Tau46 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Alzheimer Brain |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
TAU
|
Diagnostic Biosystems |
Tau46 |
0.1 ml |
Concentrate |
CE/IVD |
MOB472-01 |
-
|
| Host |
Mouse |
| Klon |
Tau46 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Alzheimer Brain |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
TAU
|
Diagnostic Biosystems |
Tau46 |
0.5 ml |
Concentrate |
CE/IVD |
MOB472-05 |
-
|
| Host |
Mouse |
| Klon |
ZM92 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human TCL1 protein fragment (around aa 2-109) |
| Lokalisation |
Cytoplasm |
TCL1
|
Zeta Corporation |
ZM92 |
1 ml |
Concentrate |
CE/IVD |
Z2402ML |
-
|
| Host |
Mouse |
| Klon |
ZM92 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human TCL1 protein fragment (around aa 2-109) |
| Lokalisation |
Cytoplasm |
TCL1
|
Zeta Corporation |
ZM92 |
7 ml |
Ready-to-use |
CE/IVD |
Z2402MP |
-
|
| Host |
Mouse |
| Klon |
ZM92 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human TCL1 protein fragment (around aa 2-109) |
| Lokalisation |
Cytoplasm |
TCL1
|
Zeta Corporation |
ZM92 |
0.5 ml |
Concentrate |
CE/IVD |
Z2402MS |
-
|
| Host |
Mouse |
| Klon |
ZM92 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human TCL1 protein fragment (around aa 2-109) |
| Lokalisation |
Cytoplasm |
TCL1
|
Zeta Corporation |
ZM92 |
0.1 ml |
Concentrate |
CE/IVD |
Z2402MT |
-
|
| Host |
Mouse |
| Klon |
3A8 |
| Format |
Purified |
| Methode |
F, IP |
| Isotyp |
Mouse IgG2a |
TCR, alpha (T-Cell Receptor)
|
Zytomed Systems GmbH |
3A8 |
100 µg |
Purified |
RUO |
620-0019 |
-
|
| Host |
Mouse |
| Klon |
3A8 |
| Format |
Purified |
| Methode |
F, IP |
| Isotyp |
Mouse IgG2a |
TCR, alpha (T-Cell Receptor)
|
Zytomed Systems GmbH |
3A8 |
50 µg |
Purified |
RUO |
620-0020 |
-
|
| Host |
Hamster |
| Klon |
H57-597 |
| Format |
Purified |
| Methode |
IP, FL |
| Isotyp |
Hamster IgG |
| Verdünnung |
Affinity purified murine T cell receptor |
TCR, alpha, beta (T-Cell Receptor)
|
Zytomed Systems GmbH |
H57-597 |
250 µg |
Purified |
RUO |
620-0021 |
-
|
| Host |
Mouse |
| Klon |
R73 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Rat T blasts and erythrocytes |
TCR, alpha, beta (T-Cell Receptor)
|
Zytomed Systems GmbH |
R73 |
100 µg |
Purified |
RUO |
620-0024 |
-
|
| Host |
Mouse |
| Klon |
V65 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
CD3 +ve TCR alpha/beta -ve rat T cell hybridoma line |
TCR, gamma, delta (T-Cell Receptor)
|
Zytomed Systems GmbH |
V65 |
250 µg |
Purified |
RUO |
620-0037 |
-
|
| Host |
Mouse |
| Klon |
SEN28 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Thymus |
| Verdünnung |
1:10 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant protein corresponding to the amino terminal region of TdT molecule |
| Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Diagnostic Biosystems |
SEN28 |
1 ml |
Concentrate |
CE/IVD |
MOB545 |
-
|
| Host |
Mouse |
| Klon |
SEN28 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Thymus |
| Verdünnung |
1:10 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant protein corresponding to the amino terminal region of TdT molecule |
| Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Diagnostic Biosystems |
SEN28 |
0.1 ml |
Concentrate |
CE/IVD |
MOB545-01 |
-
|
| Host |
Mouse |
| Klon |
SEN28 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Thymus |
| Verdünnung |
1:10 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant protein corresponding to the amino terminal region of TdT molecule |
| Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Diagnostic Biosystems |
SEN28 |
0.5 ml |
Concentrate |
CE/IVD |
MOB545-05 |
-
|
| Host |
Mouse |
| Klon |
SEN28 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Thymus |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant protein corresponding to the amino terminal region of TdT molecule |
| Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Diagnostic Biosystems |
SEN28 |
6 ml |
Ready-to-use |
CE/IVD |
PDM096 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM51 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Thymus. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa 52-192) of human DNTT protein |
| Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Zeta Corporation |
ZM51 |
1 ml |
Concentrate |
CE/IVD |
Z2391ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM51 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Thymus. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa 52-192) of human DNTT protein |
| Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Zeta Corporation |
ZM51 |
7 ml |
Ready-to-use |
CE/IVD |
Z2391MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM51 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Thymus. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa 52-192) of human DNTT protein |
| Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Zeta Corporation |
ZM51 |
0.5 ml |
Concentrate |
CE/IVD |
Z2391MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM51 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Thymus. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment (around aa 52-192) of human DNTT protein |
| Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Zeta Corporation |
ZM51 |
0.1 ml |
Concentrate |
CE/IVD |
Z2391MT |
-
|
| Host |
Mouse |
| Klon |
T2H5 |
| Format |
Purified |
| Methode |
P, F, WB, IP, EL |
| Vorbehandlung |
Citrate oder Trypsin |
| Positivkontrolle |
Human tonsil |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Native purified protein from human mammary tumour |
Tenascin
|
Zytomed Systems GmbH |
T2H5 |
200 µg (200 µl) |
Purified |
RUO |
620-0072 |
-
|
| Host |
Mouse |
| Klon |
DB7 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil, appendix |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
IgG2a |
| Lokalisation |
Extracellular |
Tenascin C (TNC)
|
Zytomed Systems GmbH |
DB7 |
0.5 ml |
Concentrate |
RUO |
MSK104-05 |
-
|
| Host |
Rabbit |
| Klon |
ZR365 |
| Format |
concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Testis |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human TFE3 protein |
| Lokalisation |
Nucleus |
TFE3
|
Zeta Corporation |
ZR365 |
1 ml |
concentrate |
CE/IVD |
Z2605RL |
-
|